METAVIA INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
METAVIA INC. (MTVA) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $130.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $130.00K, a 17.12% increase year-over-year.
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $100.00K, a 24.24% decline year-over-year.
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $97.00K, a 30.22% decline year-over-year.
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $111.00K, a 17.16% decline year-over-year.
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $411.00K, a 23.61% decline from fiscal 2024.
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $538.00K, a 142.34% increase from fiscal 2023.
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $222.00K, a 74.00% decline from fiscal 2022.
- METAVIA INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $854.00K, a 29.00% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $130.00K 10-Q · filed 2026-08-06 | $230.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $100.00K 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $411.00K 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $97.00K 10-Q · filed 2025-11-06 | $208.00K derived: sum of 2 quarters · filed 2026-08-06 | $340.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $111.00K 10-Q · filed 2026-08-06 | $243.00K derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $132.00K 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $538.00K 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $139.00K 10-Q · filed 2025-11-06 | $273.00K derived: sum of 2 quarters · filed 2025-11-06 | $378.00K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $134.00K 10-Q · filed 2025-11-06 | $239.00K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $105.00K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $222.00K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $172.00K 10-Q · filed 2024-11-07 | $196.00K derived: sum of 2 quarters · filed 2024-11-07 | $122.00K derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $24.00K 10-Q · filed 2024-11-07 | -$50.00K derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | -$74.00K 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $854.00K 10-K · filed 2024-03-28 | |||
| 2022-09-30 | $218.00K 10-Q · filed 2023-11-13 | $429.00K derived: sum of 2 quarters · filed 2023-11-13 | $636.00K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $211.00K 10-Q · filed 2023-11-13 | $418.00K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $207.00K 10-Q · filed 2023-11-13 | |||
| 2021-12-31 | $662.00K 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $107.00K 10-Q · filed 2022-11-14 | $287.00K derived: sum of 2 quarters · filed 2022-11-14 | $474.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2021-06-30 | $180.00K 10-Q · filed 2022-11-14 | $367.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | $187.00K 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | $699.00K 10-K · filed 2022-03-31 | |||
| 2020-09-30 | $209.00K 10-Q · filed 2021-11-15 | $380.00K derived: sum of 2 quarters · filed 2021-11-15 | $539.00K derived: sum of 3 quarters · filed 2021-11-15 | |
| 2020-06-30 | $171.00K 10-Q · filed 2021-11-15 | $330.00K derived: sum of 2 quarters · filed 2021-11-15 | ||
| 2020-03-31 | $159.00K 10-Q · filed 2021-11-15 | |||
| 2019-12-31 | $118.00K 10-K · filed 2021-04-15 | |||
| 2019-09-30 | $54.00K 10-Q · filed 2020-11-13 | $133.00K derived: sum of 2 quarters · filed 2020-11-13 | $193.00K derived: sum of 3 quarters · filed 2020-11-13 | |
| 2019-06-30 | $79.00K 10-Q · filed 2020-11-13 | $139.00K derived: sum of 2 quarters · filed 2020-11-13 | ||
| 2019-03-31 | $60.00K 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |